Browsing: Investing

By Brenda León Neurocrine Biosciences said Friday the Food and Drug Administration approved Ingrezza capsules to treat adults with chorea, an abnormal involuntary movement disorder associated…

It’s prime time to grab two bond funds tossing out 8%+ dividends now—and we have the Fed (of all things!) to thank for this opportunity. Last…

By Brenda León Maui Land & Pineapple shares fell in post-market trading on Friday after the company swung to a loss in the second quarter. The…

Ever since the June 29 Supreme Court ruling against affirmative action in universities, various sectors have been concerned about the implications to their work, from corporations…

By Josh Beckerman ElectraMeccanica, which previously said its merger with Tevva represented a pivot to commercial vehicles from consumer vehicles, said Friday that it won’t pursue…

By Will Feuer Regeneron Pharmaceuticals said the Food and Drug Administration has approved an eight-milligram injection of its Eylea treatment for various eye diseases. The dose…

By Will Feuer Palo Alto Networks reported a jump in earnings for its fiscal fourth quarter and issued upbeat guidance for the fiscal year. The cybersecurity…

Don’t miss these top money and investing features: Sign up here to get MarketWatch’s best mutual funds and ETF stories emailed to you weekly!INVESTING NEWS & TRENDSBears…

In 2023 so far, the U.S. economy has defied recession expectations. Latest early nowcasts from the Federal Reserve Bank of Atlanta’s GDPNow model are calling for…

The U.S. Treasury building in Washington. Nathan Howard/Bloomberg When looking for juicy yields, investors these days should stay short. Buying long-dated Treasury bonds seemed like a…